A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will evaluate the management of Tarceva-induced skin rash in patients with
non-small cell lung cancer who have failed first-line chemotherapy for advanced disease.
Eligible patients will be randomized to receive a)doxycycline 100mg po daily or b)no
preventative treatment; all patients will receive Tarceva 150mg/kg po daily. The anticipated
time on study treatment is until disease progression or intolerable toxicity, and the target
sample size is 100-500 individuals.